Utomilumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Utomilumab
Accession Number
DB15113
Type
Biotech
Groups
Investigational
Description

Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).

Synonyms
  • PF-05082566
Categories
UNII
6YY8O697VF
CAS number
1417318-27-4

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Utomilumab.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Utomilumab.
AbrilumabThe risk or severity of adverse effects can be increased when Abrilumab is combined with Utomilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Utomilumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Utomilumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Utomilumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Utomilumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Utomilumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Utomilumab.
AmatuximabThe risk or severity of adverse effects can be increased when Amatuximab is combined with Utomilumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
CD137

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentNeoplasms1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentCarcinoma, Squamous Cell of Head and Neck / Follicular Lymphoma (FL) / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Melanoma / Non-Hodgkin's Lymphoma (NHL) / Renal Cell Adenocarcinoma1
1RecruitingTreatmentCCND1 Positive / CD20 Positive / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Mantle Cell Lymphoma / Refractory Diffuse Large B Cell Lymphoma / Refractory Mantle Cell Lymphoma / Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma1
1RecruitingTreatmentCOL6A3 Positive / HLA-A*0201 Positive Cells Present / Platinum Resistant Ovarian Cancer / PRAME Positive / Recurrent Ovarian Carcinoma1
1RecruitingTreatmentColorectal Cancers / Malignant Neoplasms of Digestive Organs / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v81
1RecruitingTreatmentFollicular Lymphoma (FL)1
1RecruitingTreatmentHER2 Positive Breast Carcinoma / Recurrent Breast Carcinoma / Stage III Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1TerminatedTreatmentAdvanced/Metastatic Solid Tumors1
1, 2RecruitingTreatmentAdvanced Malignant Solid Neoplasm / Castration-Resistant Prostate Carcinoma / Malignant Neoplasm of Breast / Malignant Neoplasms of Bone and Articular Cartilage / Malignant Neoplasms of Digestive Organs / Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System / Malignant Neoplasms of Female Genital Organs / Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites / Malignant Neoplasms of Independent (Primary) Multiple Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Malignant Neoplasms of Male Genital Organs / Malignant Neoplasms of Mesothelial and Soft Tissue / Malignant Neoplasms of Respiratory and Intrathoracic Organs / Malignant Neoplasms of Thyroid and Other Endocrine Glands / Malignant Neoplasms of Urinary Tract / Malignant Solid Neoplasm / Metastatic Hormone Refractory Prostate Cancer / Metastatic Malignant Solid Neoplasm / Neoplasms of Uncertain or Unknown Behavior / Neoplasms, Malignant / Prostate Carcinoma Metastatic in the Bone / Refractory Malignant Solid Neoplasm / Stage IV Prostate Cancer AJCC v8 / Stage IVA Prostate Cancer AJCC v8 / Stage IVB Prostate Cancer AJCC v81
1, 2RecruitingTreatmentRefractory Large B-cell Lymphoma1
2Active Not RecruitingTreatmentMalignant Neoplasms of Ill-defined Secondary and Unspecified Sites / Malignant Neoplasms of Lip Oral Cavity and Pharynx / Oropharyngeal Cancers1
2RecruitingTreatmentBreast Cancer1
2RecruitingTreatmentCancer, Advanced1
2RecruitingTreatmentInvasive Breast Carcinoma / Recurrent Breast Carcinoma / Stage III Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer / Triple-Negative Breast Carcinoma1
3Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:50 / Updated on November 02, 2019 03:29